1 results match your criteria: "Cancercare Institute[Affiliation]"
Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus.
Respir Med Case Rep
June 2020
Cancercare Institute, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Article Synopsis
- Mammalian target of rapamycin inhibitors (mTORi), like sirolimus and everolimus, are medications used for treating certain cancers and in organ transplant procedures.
- Interstitial lung disease (ILD) is a potential complication associated with mTORi, with more cases linked to sirolimus compared to everolimus, possibly due to sirolimus being more widely used earlier on.
- A specific case is presented where a kidney transplant patient developed ILD from sirolimus but showed quick improvement after switching to everolimus.